Table 2.
Frequency of IDH mutations and KIAA1549‐BRAF fusion gene in nondiffuse and diffuse gliomas. Abbreviations: IDH = isocitrate dehydrogenase; WHO = World Health Organization.
| Histology* | IDH mutation† | KIAA1549‐BRAF fusion (%)‡ | |
|---|---|---|---|
| IDH1 mutation (%) | IDH2 mutation (%) | ||
| Nondiffuse glioma | |||
| Pilocytic astrocytoma | 0 | 0 | 6/13 (46.1) |
| Ganglioglioma | 0 | 0 | 2/18 (11.1) |
| Total | 0 | 0 | 8/31 (25.8) |
| Diffuse glioma | |||
| Astrocytoma II | 14 (8) | 0 | 1 (0.5) |
| Astrocytoma III | 8 (4.5) | 1 (0.5) | 0 |
| Oligodendroglioma II | 24 (13.7) | 3 (1.7) | 4 (2.2) |
| Oligodendroglioma III | 27 (15.4) | 3 (1.7) | 8 (4.4) |
| Oligoastrocytoma II | 16 (9.1) | 0 | 2 (1.1) |
| Oligoastrocytoma III | 26 (14.8) | 0 | 1 (0.5) |
| Glioblastoma IV | 3 (1.7) | 0 | 1 (0.5) |
| Total | 118 (67.4) | 7 (4) | 17 (9.4) |
*
Roman numerals refer to WHO histological grade.
†
175 cases evaluated for IDH mutations.
‡
180 cases evaluated for KIAA1549‐BRAF fusion gene.